Oral immunotherapy improves the quality of life of adults with food allergy.

IF 2.6 4区医学 Q2 ALLERGY

Allergy Asthma and Clinical Immunology Pub Date : 2024-10-14 DOI:10.1186/s13223-024-00915-6

Na'ama Epstein-Rigbi, Michael B Levy, Liat Nachshon, Yael Koren, Michael R Goldberg, Arnon Elizur

{"title":"Oral immunotherapy improves the quality of life of adults with food allergy.","authors":"Na'ama Epstein-Rigbi, Michael B Levy, Liat Nachshon, Yael Koren, Michael R Goldberg, Arnon Elizur","doi":"10.1186/s13223-024-00915-6","DOIUrl":null,"url":null,"abstract":"Background: Oral immunotherapy (OIT) has become the standard of care for children with food allergy (FA) and has substantially improved their quality of life. The effect of OIT on the quality of life in adults, however, has been studied to a much lesser degree.Methods: Patients with food allergy aged ≥ 18 years who underwent OIT at Shamir Medical Center completed the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) before and at the end of treatment. Adults with FA not undergoing OIT who completed the FAQLQ-AF at 2 time points, served as controls.Results: A total of 44 adults, median age 23.4 years, who underwent OIT for milk (n = 19), egg (n = 2), peanut (n = 9), sesame (n = 6), and tree nuts (n = 8), and 11 controls were studied. The median OIT starting dose was 23.8 mg protein. 33 patients (75%) reached full desensitization within a median of 10.3 months. The FAQLQ-AF baseline scores were comparable between the study and control groups for all items except for Food Allergy related Health (FAH) item in which the study group had a significantly better score (p = 0.02). At the second time point, the study group had significantly better scores in all items (Allergen Avoidance and Dietary Restrictions (AADR), p = 0.02; and Emotional Impact (EI), Risk of Allergen Exposure (RAE), FAH and the Total Score, p < 0.01). The change in scores for the study group was significantly better, statistically and clinically, in AADR, p = 0.04; EI, p < 0.01; RAE, p = 0.01, and in the total score, p = 0.01.Conclusions: OIT significantly improves quality of life of adults with FA. This finding adds important support for providing OIT in this population.","PeriodicalId":51302,"journal":{"name":"Allergy Asthma and Clinical Immunology","volume":"20 1","pages":"53"},"PeriodicalIF":2.6000,"publicationDate":"2024-10-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11472437/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Allergy Asthma and Clinical Immunology","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s13223-024-00915-6","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"ALLERGY","Score":null,"Total":0}

引用次数: 0

Abstract

Background: Oral immunotherapy (OIT) has become the standard of care for children with food allergy (FA) and has substantially improved their quality of life. The effect of OIT on the quality of life in adults, however, has been studied to a much lesser degree.

Methods: Patients with food allergy aged ≥ 18 years who underwent OIT at Shamir Medical Center completed the Food Allergy Quality of Life Questionnaire-Adult Form (FAQLQ-AF) before and at the end of treatment. Adults with FA not undergoing OIT who completed the FAQLQ-AF at 2 time points, served as controls.

Results: A total of 44 adults, median age 23.4 years, who underwent OIT for milk (n = 19), egg (n = 2), peanut (n = 9), sesame (n = 6), and tree nuts (n = 8), and 11 controls were studied. The median OIT starting dose was 23.8 mg protein. 33 patients (75%) reached full desensitization within a median of 10.3 months. The FAQLQ-AF baseline scores were comparable between the study and control groups for all items except for Food Allergy related Health (FAH) item in which the study group had a significantly better score (p = 0.02). At the second time point, the study group had significantly better scores in all items (Allergen Avoidance and Dietary Restrictions (AADR), p = 0.02; and Emotional Impact (EI), Risk of Allergen Exposure (RAE), FAH and the Total Score, p < 0.01). The change in scores for the study group was significantly better, statistically and clinically, in AADR, p = 0.04; EI, p < 0.01; RAE, p = 0.01, and in the total score, p = 0.01.

Conclusions: OIT significantly improves quality of life of adults with FA. This finding adds important support for providing OIT in this population.

查看原文本刊更多论文

口服免疫疗法可改善食物过敏成人的生活质量。

背景：口服免疫疗法（OIT）已成为食物过敏（FA）儿童的标准治疗方法，并大大改善了他们的生活质量。然而，有关口服免疫疗法对成人生活质量影响的研究却少得多：方法：在沙米尔医疗中心接受 OIT 治疗的年龄≥ 18 岁的食物过敏患者在治疗前和治疗结束时填写食物过敏生活质量问卷-成人表 (FAQLQ-AF)。未接受 OIT 治疗的成人食物过敏者作为对照组，在两个时间点填写 FAQLQ-AF：共有 44 名成人（中位年龄为 23.4 岁）接受了牛奶（19 人）、鸡蛋（2 人）、花生（9 人）、芝麻（6 人）和树坚果（8 人）的 OIT 治疗，另有 11 名对照组接受了研究。OIT 起始剂量的中位数为 23.8 毫克蛋白质。33 名患者（75%）在中位数 10.3 个月内达到完全脱敏。研究组和对照组的 FAQLQ-AF 基线得分除食物过敏相关健康（FAH）项目外，其他项目均相当，研究组的得分明显高于对照组（P = 0.02）。在第二个时间点，研究组在所有项目上的得分都明显高于对照组（过敏原避免和饮食限制（AADR），p = 0.02；情绪影响（EI）、过敏原暴露风险（RAE）、食物过敏相关健康（FAH）和总分，p 结论：OIT 能明显改善食物过敏患者的生活质量：OIT 能明显改善 FA 成人的生活质量。这一发现为在这一人群中提供 OIT 提供了重要支持。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Allergy Asthma and Clinical Immunology ALLERGY-IMMUNOLOGY

CiteScore

4.30

自引率

3.70%

发文量

审稿时长

12 weeks

期刊介绍： Allergy, Asthma & Clinical Immunology (AACI), the official journal of the Canadian Society of Allergy and Clinical Immunology (CSACI), is an open access journal that encompasses all aspects of diagnosis, epidemiology, prevention and treatment of allergic and immunologic disease. By offering a high-visibility forum for new insights and discussions, AACI provides a platform for the dissemination of allergy and clinical immunology research and reviews amongst allergists, pulmonologists, immunologists and other physicians, healthcare workers, medical students and the public worldwide. AACI reports on basic research and clinically applied studies in the following areas and other related topics: asthma and occupational lung disease, rhinoconjunctivitis and rhinosinusitis, drug hypersensitivity, allergic skin diseases, urticaria and angioedema, venom hypersensitivity, anaphylaxis and food allergy, immunotherapy, immune modulators and biologics, immune deficiency and autoimmunity, T cell and B cell functions, regulatory T cells, natural killer cells, mast cell and eosinophil functions, complement abnormalities.